Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide

Discontinued Product

Unfortunately Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide (Cat. No. 2106) has been withdrawn from sale for commercial reasons.
Cat.No. 2106 - Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide | Leu-Ile-Pro-Gln-Gln-pSer-Ile-Asn-Glu-Ala-Ile-[Lys]
Description: Blocking peptide (phosphorylated) for anti-phospho-GluR1 (Ser831) (Cat. No. 2041)

Biological Activity

Synthetic peptide (LIPQQ(pS)INEAI[K]) corresponding to amino acids 826-836 of rat mature GluR1 (Accession No. P19490), with a phosphorylated serine at position 831, and a lysine added to the C-terminus for conjugation. Immunogen used for anti-phospho-GluR1 (Ser831) (Cat. No. 2041).

Technical Data

M. Wt 1433.56
Formula C60H105N16O22P

(Modifications: Ser-6 = pSer)

Storage Desiccate at -20°C
Smiles [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](COP(O)(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Preparing Stock Solutions

The following data is based on the product molecular weight 1433.56. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 0.7 mL 3.49 mL 6.98 mL
5 mM 0.14 mL 0.7 mL 1.4 mL
10 mM 0.07 mL 0.35 mL 0.7 mL
50 mM 0.01 mL 0.07 mL 0.14 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis is currently unavailable
on-line. Please contact Customer Service
Safety Datasheet


References are publications that support the products' biological activity.

View Related Products by Target

Keywords: Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide, supplier, Blocking, peptides, phosphorylated, anti-phospho-GluR1, Ser831, Glutamate, AMPA, Receptors, iGluR, Ionotropic, immunogen, AMPA, Receptors, AMPA, Receptors, Tocris Bioscience

Citations for Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide

Citations are publications that use Tocris products.

Currently there are no citations for Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide.

Reviews for Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide

There are currently no reviews for this product. Be the first to review Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide and earn rewards!

Have you used Anti-phospho-GluR1 (Ser831) phosphorylated blocking peptide?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area


Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.


Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.


Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.


Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.